Foundery Immune Studio Drives Innovation in Immunotherapy
TREM1, TREM2, MARCO immune tuning therapies to develop in solid cancer, autoimmune, and fibrotic diseases
Foundery Immune Studio, LLC, is a biotechnology venture studio dedicated to turning groundbreaking immunology findings into effective treatments. Recently, the company announced its rights acquisition for three advanced immune tuning therapies developed by Ikena Oncology, Inc.
Innovative Therapies in Development
These next-generation monoclonal antibodies signify a notable shift from traditional immunotherapies that primarily focus on immune T cells. Instead, they are designed to fine-tune the immune responses associated with cancer by targeting myeloid cells. These myeloid cells, found throughout various tissues, can represent a significant portion of the tumor microenvironment. This innovation aims to bring about a sophisticated recalibration of the immune environment, enhancing the effectiveness of cancer treatments.
The Importance of Myeloid Cells
Myeloid cells play vital roles in a variety of diseases, including cancer, fibrotic conditions, autoimmune disorders, and neurodegenerative diseases such as Alzheimer’s. By selectively engaging with specific receptors like TREM1, TREM2, and MARCO, these therapies aim to recalibrate immune responses, nurturing a more conducive environment for treatment.
Clinical Progress and Challenges
The therapies PY314 and PY159, targeting TREM2 and TREM1, respectively, have successfully completed initial Phase 1 clinical trials demonstrating good tolerance and promising pharmacodynamic results both alone and in combination with existing treatments such as pembrolizumab. Meanwhile, the third candidate targeting MARCO is ready to transition towards Investigational New Drug (IND) status, poised for further development.
Strategic Expansion through Subsidiaries
In pursuit of its mission, Foundery Immune Studio is gearing up to introduce its first subsidiary, RhBio, LLC. This new entity will focus on honing the therapeutic applications of these innovative treatments in solid cancers, autoimmune, and fibrotic diseases.
Expert Commentary on Myeloid Cell Targeting
“The concept of tuning myeloid cells, rather than just focusing on T cells, holds transformative potential for treating a range of diseases,” claims Matthew "Max" Krummel, PhD, a prominent figure in immunology research and co-founder of related ventures. He emphasizes that understanding the immune phenotype of tumors could unlock new methodologies for addressing diverse health challenges including cancers and autoimmune disorders.
Leadership and Development Team
The groundwork for these therapies is being laid by the formidable trio of founders at Foundery Immune Studio: Dr. Venkataraman Sriram, Dr. Michel Streuli, and Dr. Max Krummel. Their extensive backgrounds in myeloid cell biology and the development of successful therapies uniquely position them to overcome obstacles that have hindered previous advancements in the field.
About Foundery Immune Studio
Based in San Francisco, Foundery Immune Studio embodies a collaborative, scientist-led approach to biotechnology. Utilizing a venture studio model, it strives to expedite early-stage research and development. This team boasts a track record of creating commercially successful immunotherapies that have generated global revenues exceeding $100 billion. Their aim is to address pressing medical needs through innovative biotherapeutic solutions targeting dysfunctions within the immune system, heralding a new era of treatment opportunities.
Frequently Asked Questions
What are the primary focus areas for Foundery Immune Studio?
Foundery Immune Studio is focused on developing therapies for solid cancers, autoimmune diseases, and fibrotic diseases.
What is the significance of targeting myeloid cells?
Targeting myeloid cells can enhance the immune response in tumors and improve treatment outcomes in various diseases.
What therapies has Foundery Immune Studio acquired?
Foundery Immune Studio has acquired rights to three clinical-stage immune tuning therapies from Ikena Oncology, including PY314, PY159, and PY265.
Who are the founders of Foundery Immune Studio?
The founders are Dr. Venkataraman Sriram, Dr. Michel Streuli, and Dr. Matthew Krummel, each with extensive experience in immunotherapy development.
What approach does Foundery take in the biotech sector?
Foundery employs a scientist-driven venture studio model to accelerate early research and development of transformative therapies.
